Answers are grounded in this paper and cite their sources.
Evaluates diagnostic performance of GXT96 X3 and FluoroType assay for SARS-CoV-2 detection, suggesting reliable variant screening.
Background: The continued evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) created ongoing challenges for molecular diagnostics and variant surveillance. Assays capable of maintaining diagnostic sensitivity across emerging variants while providing variant-related information remain essential for clinical and public health applications. This study evaluated the performance of the GXT96 X3 extraction kit in combination with the FluoroType® SARS-CoV-2 varID Q version 1.0 assay (Hain LifeScience SA (Pty) Ltd., South Africa) for the detection, semi-quantitative assessment, and variant characterization of SARS-CoV-2 under laboratory conditions. Methods: A total of 220 samples were evaluated, including residual nasopharyngeal clinical specimens (n = 183), reference materials, and cultured SARS-CoV-2 virus dilutions. Residual specimens collected during multiple COVID-19 waves in South Africa (wild-type, Beta, Delta, and Omicron) were compared against standard-of-care (SOC) molecular assays used for routine diagnosis. RNA extraction was performed using the automated GXT96 X3 platform, followed by amplification on the FluoroCycler® XT using the FluoroType® SARS-CoV-2 varID Q assay targeting RdRp and N genes, with additional spike gene mutation detection for variant detection. Diagnostic accuracy, agreement (Cohen’s kappa), precision, linearity, and limit of detection (LoD) were assessed. Results: The assay demonstrated a sensitivity of 98.4% (95% CI: 94.2–99.8) and specificity of 100% (95% CI: 95.9–100.0) compared with SOC assays, with an overall agreement of κ = 0.981. Precision analysis showed acceptable reproducibility with a standard deviation of ≤1.49 and a coefficient of variation of ≤3.83%. Regression analysis demonstrated linearity across the dilution series (R2 = 0.9882 for RdRp and 0.994 for N genes). The LoD was ≤100 copies/mL for the RdRp gene and 250 copies/mL for the N gene. Variant-associated spike mutations corresponded broadly with epidemiological wave patterns observed in South Africa. Conclusions: Under the evaluated laboratory conditions, the GXT96 X3 extraction platform combined with the FluoroType® SARS-CoV-2 varID Q assay demonstrated high diagnostic accuracy and reproducibility for SARS-CoV-2 detection across a range of viral loads with additional spike gene mutation detection as an adjunct feature.
No takes yet. Share an insight, caveat, or question.
Munir et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: